AU Patent

AU2013211489A1 — Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Assigned to Novartis AG · Expires 2013-08-22 · 13y expired

What this patent protects

H:\ixp~nienvoven\NRPortb\DCC\IXP\5354969_I.DOC-2JAi7/21 3 Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3 (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes. Idao 2-TheS - Scate Figu…

USPTO Abstract

H:\ixp~nienvoven\NRPortb\DCC\IXP\5354969_I.DOC-2JAi7/21 3 Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3 (4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes. Idao 2-TheS - Scate Figure 1

Drugs covered by this patent

Patent Metadata

Patent number
AU2013211489A1
Jurisdiction
AU
Classification
—
Expires
2013-08-22
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.